Inogen, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

Summary of Significant Accounting Policies - Additional Information (Details) (USD $) In Thousands, except Share data, unless otherwise specified	1 Months Ended	3 Months Ended						1 Months Ended		3 Months Ended
	Nov. 11, 2013	Mar. 31, 2014 Product Segment	Mar. 31, 2013	Mar. 07, 2014	Feb. 20, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 20, 2014 Inogen Inc	Feb. 20, 2014 Stockholders	Mar. 31, 2014 total revenue	Mar. 31, 2013 total revenue	Mar. 31, 2014 Medicare Service Reimbursement Programs	Mar. 31, 2013 Medicare Service Reimbursement Programs	Mar. 31, 2014 Medicare Service Reimbursement Programs rental revenue	Mar. 31, 2013 Medicare Service Reimbursement Programs rental revenue	Mar. 31, 2014 Accounts Receivable	Mar. 31, 2013 Accounts Receivable	Mar. 31, 2014 raw materials vendor one	Mar. 31, 2013 raw materials vendor one	Mar. 31, 2014 raw materials vendor two	Mar. 31, 2013 raw materials vendor two	Mar. 31, 2014 raw materials vendor three	Mar. 31, 2013 raw materials vendor three	Mar. 31, 2014 Accounts payable vendor one	Mar. 31, 2013 Accounts payable vendor one	Mar. 31, 2014 Accounts payable vendor two	Mar. 31, 2013 Accounts payable vendor two	Mar. 31, 2014 Accounts payable vendor three	Mar. 31, 2013 Accounts payable vendor three	Mar. 31, 2014 Service Contracts
Significant Accounting Policies [Line Items]
Extended service contracts		Lifetime of the patient																												12 to 24 months
Accrual of product warranty liability		$ 921	$ 694			$ 809	$ 447
Number of deliverables qualifying as separate units		2
Deliverable standard warranty, period		3 years
Deliverable lifetime warranty,description		Lifetime of the patient																												12 to 24 months
Estimation for sale of products		The Company estimates that 60% of patients will succumb to their disease within three years. Given the approximate mortality rate of 20% per year, the Company estimates on average all patients will succumb to their disease within five years.
Rental revenue earned		30-day period
Unbilled Receivables		2,413				1,435
Fair Value Inputs, Long-term Revenue Growth Rate										10.00%	10.00%	21.50%	26.30%	58.00%	60.40%	34.40%	25.00%	18.80%	14.00%	17.80%	13.80%	10.50%	12.10%	19.50%	18.30%	8.60%	9.60%	7.40%	6.70%
Accounts Receivable, Net, Current		18,084				10,231										6,229	2,560
Accounts Payable Current																								1,416	1,268	623	666	541	460
Cost Of Property Repairs And Maintenance		390	260
Property Plant And Equipment Salvage Value		$ 0
Number Of Operating Segments		1
Reverse stock split ratio	3:1
Effective date of reverse stock split		Nov. 12, 2013
Common stock, par value	$ 0.001	$ 0.001			$ 16.00	$ 0.001
Common stock, shares issued		18,151,551			4,411,763	280,974
Number of shares sold								3,529,411	882,352
Common stock purchased by underwriters				99,550
Common stock, shares outstanding		18,151,551			14,259,647	280,974